Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead
Radhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria · 2025
Read Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead by Radhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722561.txt.
Description
Radhika Arya and co-authors weigh how to handle returning gut infections if a key preventive antibody leaves the scene. Their 2025 paper deals with Clostridioides difficile, a leading cause of hospital diarrhea, which comes back in a fifth to a third of patients. Stewardship and better testing have trimmed rates, yet recurrence keeps rising.
The antibody, bezlotoxumab, shields the colon wall from the germ's toxin B. Trials cut recurrence from 26 to 16 percent when it rode alongside standard antibiotics. Guidelines endorsed it in 2021 for first and later recurrences, while noting the logistics are awkward. The authors map the challenges ahead without it, from cost and access to which patients lose the most protection.
Catalog record
| CREATOR | Radhika Arya, Alex N Zimmet, Marisa Holubar, William Alegria |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |